Healthy
Conditions
Keywords
Ladotyri Mytilinis PDO cheese, Postprandial response
Brief summary
The purpose of this study was the investigation of the postprandial metabolic responses, after the intake of a traditional, Ladotyri Mytilinis cheese, compared to corresponding responses after an Italian Parmesan cheese consumption, in healthy participants.
Detailed description
A pilot cross-over, randomized and single-blinded, intervention-clinical trial was conducted, in ten healthy men and women subjects, aged eighteen to thirty years, after random allocation into the control and the intervention group, received a high-fat and carbohydrates meal, containing Ladotyri Mytilinis (the authentic nonrefrigerated recipe) or Italian Parmesan, PDO cheeses. After a washout week, participants consumed the same meals, conversely. Differences on postprandial responses of serum total, High Density Lipoprotein (HDL-), Low Density Lipoprotein (LDL-) cholesterol, glucose, triglycerides and uric acid levels, as well as of plasma total antioxidant capacity according to Ferric Reducing Antioxidant Power method, were determined between groups in fasting, thirty minutes, one and a half hour, and three hours after meal intake.
Interventions
Branding PDO cheese from Mytilini, purchasing by E.Thimelis Dairy S.A.
Branding Parmesan PDO cheese from Italy, supplied by LIDL Hellas
Sponsors
Study design
Masking description
Only investigator knew the type of meal, consumed by each participant
Intervention model description
In the first trial period, participants in arm a consumed a meal containing 100g of white wheat bread and 80g of Italian Parmesan PDO cheese and arm b participants consumed a meal containing 100g of white wheat bread and 80g of Authentic Ladotyri Mytilinis PDO cheese. After a washout week participants consumed the meals, in reverse.
Eligibility
Inclusion criteria
* Age 18-65 years * Willingness to join and complete the nutritional intervention
Exclusion criteria
* Inability or unwillingness to provide informed consent * Three-month nutritional supplement * Age over 65 years or below 18 years * Chronic diseases history * Hemoglobin A1c - HbA1c \> 5.7 % * Abnormal Body Mass Index (BMI) (\> 25 kg / m2) * Abnormal hematological or biochemical profile (total cholesterol \> 240 mg/dL, triglycerides \> 250 mg/dL, glucose \> 100 mg/dL) * Alcohol overdose (\> 40 g alcohol / day) * Heavy smoking (\> 10 cigarettes / day) * Concurrent participation in another intervention study or unconsciousness in previous blood draws
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline of Total Antioxidant Capacity at 30 minutes, 1.5 hours and 3 hours | 3 hours | Plasma antioxidant activity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline of glucose at 30 minutes, 1.5 hours and 3 hours | 3 hours | Serum glucose levels |
| Changes from baseline of total Cholesterol at 30 minutes, 1.5 hours and 3 hours | 3 hours | Serum total cholesterol levels |
| Changes from baseline of High Density Lipoprotein cholesterol (HDL-) at 30 minutes, 1.5 hours and 3 hours | 3 hours | Serum High Density Lipoprotein levels |
| Changes from baseline of Low Density Lipoprotein cholesterol (LDL-) at 30 minutes, 1.5 hours and 3 hours | 3 hours | Serum High Density Lipoprotein levels |
| Changes from baseline of triglycerides at 30 minutes, 1.5 hours and 3 hours | 3 hours | Serum triglycerides levels |
| Changes from baseline of Uric Acid at 30 minutes, 1.5 hours and 3 hours | 3 hours | Serum uric acid levels |
Countries
Greece